43 Recruiting Solid Tumors Phase 1 Clinical Trials
Active phase 1 studies for solid tumors enrolling across the USA. Verify eligibility and contact site coordinators.
All Solid Tumors studiesPhase 1 Studies for Solid Tumors
Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors
📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
View Study & Checklist ➔Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
📍 Research Site — Edmonton, Alberta
View Study & Checklist ➔Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
📍 University of California - Los Angeles - 300208353 — Santa Monica, California
View Study & Checklist ➔Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
📍 Angeles Clinic and Research Institute — Los Angeles, California
View Study & Checklist ➔Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
📍 Phoenix Children's Hospital — Phoenix, Arizona
View Study & Checklist ➔A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
📍 The Angeles Clinic and Research Institute — Los Angeles, California
View Study & Checklist ➔A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
📍 University of Arizona Cancer Center, 3838 N. Campbell Avenue, RM 2111, Site 203 — Tucson, Arizona
View Study & Checklist ➔Study of INCB123667 in Subjects With Advanced Solid Tumors
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
📍 Florida Cancer Specialists-Sarasota-61670 — Sarasota, Florida
View Study & Checklist ➔Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔GEN1046 Safety Trial in Patients With Malignant Solid Tumors
📍 Mayo Clinic — Phoenix, Arizona
View Study & Checklist ➔Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors
📍 Children's National Medical Center — Washington D.C., District of Columbia
View Study & Checklist ➔A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
📍 UCLA Healthcare Hematology-Oncology — Santa Monica, California
View Study & Checklist ➔A Study of ADRX-0706 in Select Advanced Solid Tumors
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
📍 Yale University — New Haven, Connecticut
View Study & Checklist ➔Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
📍 Smilow Cancer Hospital Phase 1 Unit — New Haven, Connecticut
View Study & Checklist ➔Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
📍 Rigshospitalet — København Ø,
View Study & Checklist ➔Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
📍 University of California San Diego — La Jolla, California
View Study & Checklist ➔Study of AUBE00 in Patients With Solid Tumors
📍 South Texas Accelerated Research Therapeutics (START) Midwest — Grand Rapids, Michigan
View Study & Checklist ➔JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
📍 Henry Ford Health System — Detroit, Michigan
View Study & Checklist ➔A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
📍 GSK Investigational Site — Birmingham, Alabama
View Study & Checklist ➔A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
📍 The Angeles Clinic and Research Institute — Los Angeles, California
View Study & Checklist ➔JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
📍 Research Site — Denver, Colorado
View Study & Checklist ➔DPTX3186 in Wnt Pathway Activated Solid Tumors
📍 NEXT San Antonio — San Antonio, Texas
View Study & Checklist ➔A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔QTX3034 in Patients With KRAS G12D Mutation
📍 UCLA Hematology/Oncology — Los Angeles, California
View Study & Checklist ➔A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
📍 Valkyrie Clinical Trials — Los Angeles, California
View Study & Checklist ➔ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
📍 UH Cleveland Medical Center — Cleveland, Ohio
View Study & Checklist ➔A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
📍 Mayo Clinic Hospital — Phoenix, Arizona
View Study & Checklist ➔A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
📍 Exelixis Clinical Site #5 — Rogers, Arkansas
View Study & Checklist ➔Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
📍 Zai Lab Site 02003 — Los Angeles, California
View Study & Checklist ➔A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
📍 The University of Texas Md Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Study of HS-20110 in Participants With Advanced Solid Tumors
📍 BRCR Medical Center INC — Tamarac, Florida
View Study & Checklist ➔ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
📍 NYU Langone Health — New York, New York
View Study & Checklist ➔A Study of GEN1106 in Participants With Solid Tumors
📍 Yale Cancer Center — New Haven, Connecticut
View Study & Checklist ➔S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
📍 Angeles Clinic and Research Center — Los Angeles, California
View Study & Checklist ➔A Study of ZL-1310 in Participants With Selected Solid Tumors
📍 University of California San Francisco/Helen Diller Family Comprehensive Cancer Center — San Francisco, California
View Study & Checklist ➔Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
📍 City of Hope — Duarte, California
View Study & Checklist ➔First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
📍 City of Hope — Duarte, California
View Study & Checklist ➔Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
📍 Mayo Clinic - Arizona — Pheonix, Arizona
View Study & Checklist ➔